Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma
An Open-Label, Phase II Clinical Study Evaluating the Efficacy and Safety of Pemigatinib in Combination With a PD-1 Inhibitor, With or Without Chemotherapy, in Patients With Unresectable or Metastatic Cholangiocarcinoma Harboring FGFR2 Fusions or Rearrangements
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Shi Feng
- Numero di telefono: +86-10-69156042
- Email: fengshi0726@163.com
Luoghi di studio
-
-
-
Beijing, Cina, 100730
- Reclutamento
- Peking Union Medical College Hospital
-
Contatto:
- Haitao Zhao
- Numero di telefono: 86-10-69156042
- Email: zhaoht@pumch.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
1. Male or female patients aged 18 to 80 years. 2. Histologically or cytologically confirmed unresectable locally advanced or metastatic biliary tract cancer (Stage III or IV according to the AJCC Cancer Staging Manual, 2010).
3. At least one measurable lesion according to RECIST version 1.1. 4. Histologically confirmed FGFR2 fusion or rearrangement. 5. No prior treatment with a selective FGFR inhibitor, including pemigatinib, futibatinib, or other selective FGFR inhibitors.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Estimated life expectancy of at least 6 months. 8. Adequate organ function, defined by the following laboratory criteria:
- Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, without granulocyte colony-stimulating factor support within 14 days before assessment.
- Platelet count ≥ 90 × 10⁹/L, without transfusion within 14 days before assessment.
- Hemoglobin > 9 g/dL, without transfusion or erythropoiesis-stimulating agent use within 14 days before assessment.
- Total bilirubin ≤ 2.5 × the upper limit of normal (ULN).
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; for patients with liver metastases, AST or ALT ≤ 5.0 × ULN is permitted.
- Serum creatinine ≤ 1.5 × ULN and creatinine clearance, calculated using the Cockcroft-Gault formula, ≥ 50 mL/min.
- Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN. Patients receiving anticoagulant therapy are eligible if their PT is within the intended therapeutic range of the anticoagulant.
9.Women of childbearing potential must have a negative urine or serum pregnancy test within 3 days before the first administration of study treatment (Cycle 1, Day 1). A serum pregnancy test is required if a negative urine pregnancy test cannot be confirmed. Women not of childbearing potential are defined as those who have been postmenopausal for at least 1 year or have undergone surgical sterilization or hysterectomy.
10.All participants with reproductive potential, regardless of sex, must agree to use highly effective contraception, with a failure rate of less than 1% per year, throughout the treatment period and for 120 days after the last dose of study treatment (or 180 days after the last dose of chemotherapy, if applicable).
Exclusion Criteria:
- Diagnosis of another malignancy within 5 years before the first dose of study treatment, except for definitively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has been curatively resected.
- Prior treatment with a selective FGFR inhibitor.
- Failure to adequately recover from toxicities and/or complications resulting from any prior intervention before treatment initiation (i.e., recovery to Grade ≤ 1 or baseline), except for fatigue or alopecia.
- Known symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may be eligible if they are clinically stable, have no radiographic evidence of progression for at least 4 weeks before the first dose of study treatment, have no evidence of new or enlarging brain metastases on repeat imaging, and have not required steroid treatment for at least 14 days before the first dose of study treatment. Patients with carcinomatous meningitis are excluded regardless of clinical stability.
- Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Any of the following laboratory abnormalities:
1)Serum phosphate level > ULN. 2)Serum calcium outside the normal range, or albumin-corrected serum calcium outside the normal range if serum albumin is outside the normal range.
3)Potassium level below the lower limit of normal. Potassium supplementation is permitted to correct the potassium level during screening.
7. Known history of human immunodeficiency virus (HIV) infection or a confirmed positive HIV test result.
8. Active or clinically uncontrolled serious infection. 9. Clinically significant pleural effusion, ascites, or pericardial effusion requiring drainage.
10. Acute or chronic active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, defined as HBV DNA > 2,000 IU/mL or > 10⁴ copies/mL, HCV RNA > 10³ copies/mL, or concurrent positivity for hepatitis B surface antigen (HBsAg) and anti-HCV antibodies. Patients whose viral load decreases below these thresholds after nucleos(t)ide analogue antiviral therapy may be eligible.
11. Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months before the first dose of study treatment, New York Heart Association (NYHA) Class III or IV congestive heart failure, or uncontrolled arrhythmia. Patients with a pacemaker or atrial fibrillation with well-controlled heart rate may be eligible. Patients with clinically significant electrocardiogram (ECG) abnormalities or relevant cardiac history, as determined by the investigator, are also excluded.
12. Uncontrolled hypertension despite optimal medical treatment, defined as systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg, or a history of hypertensive crisis or hypertensive encephalopathy.
13. Hepatic encephalopathy, hepatorenal syndrome, Child-Pugh liver function score > 7, or more severe cirrhosis.
14. Major surgery, including craniotomy, thoracotomy, or laparotomy, within 4 weeks before the first dose of study treatment, or anticipated need for major surgery during the study treatment period.
15. Pregnant or breastfeeding women, or participants who expect to conceive or father a child during the period from the screening visit through completion of the safety follow-up visit (for male participants, through 90 days after the last dose).
16. Radiotherapy within 4 weeks before the first dose of study treatment. All radiotherapy-related toxicities must have resolved, corticosteroid treatment must not be required, and radiation pneumonitis must be excluded. A 2-week washout period is permitted for palliative radiotherapy to non-CNS lesions.
17. History of disorders of calcium-phosphate metabolism or systemic electrolyte metabolic imbalance associated with ectopic soft-tissue calcification. This excludes calcification of soft tissues, such as the skin, kidneys, tendons, or blood vessels, caused by injury, disease, or advanced age without systemic electrolyte metabolic imbalance.
18. Clinically significant corneal or retinal disease confirmed by ophthalmologic examination.
19. Use of any strong CYP3A4 inhibitor or inducer within 14 days or 5 half-lives before the first dose of study treatment, whichever is shorter. Topical ketoconazole is permitted.
20. Known hypersensitivity to pemigatinib or any excipient in the pemigatinib study drug product.
21. Inability or unwillingness to swallow pemigatinib, or clinically significant gastrointestinal disease that may interfere with the absorption, metabolism, or excretion of pemigatinib.
22. History of vitamin D deficiency requiring vitamin D supplementation at supraphysiologic doses, excluding routine dietary vitamin D supplementation.
23. Prior immune checkpoint inhibitor treatment associated with Grade ≥ 3 immune-related adverse events (irAEs).
24. Any other acute or chronic medical condition, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or administration of study treatment, interfere with interpretation of study results, or render the participant unsuitable for study participation in the investigator's judgment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: First-line
|
Pemigatinib will be administered orally once daily in a self-administered manner.
Each treatment cycle will consist of 21 days, including 14 consecutive days of treatment followed by a 7-day treatment-free period.
The dose will be 13.5 mg once daily.
PD-1 inhibitors are not restricted to a specific agent.
Commonly used agents include pembrolizumab and toripalimab.
PD-1 inhibitors will be administered by intravenous infusion on Day 1 of each 21-day cycle (Q3W).
The recommended doses are 200 mg for pembrolizumab and 240 mg for toripalimab.
The dosage and administration of other PD-1 inhibitors will be based on the respective product labeling.
The decision to administer combination chemotherapy will be made by the investigator based on a comprehensive assessment of the patient's performance status, organ function, and personal preferences.
Combination chemotherapy is generally recommended as part of the standard treatment regimen; however, it may be omitted in patients who are unable to tolerate chemotherapy due to poor general condition or impaired organ function.
If combination chemotherapy is administered, the chemotherapeutic agents will be given by intravenous infusion on Day 1 of each 21-day treatment cycle, with one cycle consisting of 3 weeks (Q3W).
The most commonly used chemotherapy regimen is the GEMOX regimen.
|
|
Sperimentale: Second-line
|
Pemigatinib will be administered orally once daily in a self-administered manner.
Each treatment cycle will consist of 21 days, including 14 consecutive days of treatment followed by a 7-day treatment-free period.
The dose will be 13.5 mg once daily.
PD-1 inhibitors are not restricted to a specific agent.
Commonly used agents include pembrolizumab and toripalimab.
PD-1 inhibitors will be administered by intravenous infusion on Day 1 of each 21-day cycle (Q3W).
The recommended doses are 200 mg for pembrolizumab and 240 mg for toripalimab.
The dosage and administration of other PD-1 inhibitors will be based on the respective product labeling.
The decision to administer combination chemotherapy will be made by the investigator based on a comprehensive assessment of the patient's performance status, organ function, and personal preferences.
Combination chemotherapy is generally recommended as part of the standard treatment regimen; however, it may be omitted in patients who are unable to tolerate chemotherapy due to poor general condition or impaired organ function.
If combination chemotherapy is administered, the chemotherapeutic agents will be given by intravenous infusion on Day 1 of each 21-day treatment cycle, with one cycle consisting of 3 weeks (Q3W).
The most commonly used chemotherapy regimen is the GEMOX regimen.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PFS, progression free survival
Lasso di tempo: From date of randomization until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 24 months.
|
Progression-Free Survival was defined as the time from treatment initiation to the first occurrence of disease progression or death from any cause.
|
From date of randomization until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 24 months.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective response rate (ORR)
Lasso di tempo: From date of randomization until the date of last tumor assessment, with tumor response evaluated every 6-9 weeks up to 24 months; objective response is defined as confirmed CR or PR per RECIST v1.1 criteria.
|
Proportion of participants with a best overall response of complete response or partial response according to RECIST version 1.1, as assessed by investigators.
Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance.
|
From date of randomization until the date of last tumor assessment, with tumor response evaluated every 6-9 weeks up to 24 months; objective response is defined as confirmed CR or PR per RECIST v1.1 criteria.
|
|
Disease control rate
Lasso di tempo: From date of randomization until the date of last tumor assessment, with disease status evaluated every 6-9 weeks up to 24 months; disease control is defined as confirmed CR, PR, or stable disease (SD) per RECIST v1.1 criteria.
|
Proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST version 1.1, as assessed by investigators.
Tumor assessments were performed at baseline, every two treatment cycles during induction (each treatment cycle was 21 days), and approximately every 6-9 weeks during maintenance.
|
From date of randomization until the date of last tumor assessment, with disease status evaluated every 6-9 weeks up to 24 months; disease control is defined as confirmed CR, PR, or stable disease (SD) per RECIST v1.1 criteria.
|
|
Overall Survival (OS)
Lasso di tempo: From date of randomization until the date of death from any cause or the date of last valid follow-up, whichever came first, assessed up to 24 months.
|
Overall survival was defined as the time from the first dose of study treatment to death from any cause.
|
From date of randomization until the date of death from any cause or the date of last valid follow-up, whichever came first, assessed up to 24 months.
|
|
Safety and Tolerability
Lasso di tempo: From the date of first study drug administration until 30 days after the date of last study drug administration, with all adverse events monitored and documented continuously throughout the treatment period and post-treatment follow-up.
|
The incidence, type, and severity of adverse events, treatment-related adverse events, serious adverse events, and clinically significant abnormalities in laboratory test results and vital signs.
Adverse events were graded according to NCI CTCAE version 5.0.
|
From the date of first study drug administration until 30 days after the date of last study drug administration, with all adverse events monitored and documented continuously throughout the treatment period and post-treatment follow-up.
|
|
DoR, duration of response
Lasso di tempo: From the date of first confirmed complete response (CR) or partial response (PR) until the date of disease progression or death from any cause, whichever came first, assessed up to 24 months.
|
DoR was measured from the date of the first documented objective tumor response (per RECIST 1.1 criteria) to the date of the first documented progression or death from any cause.
|
From the date of first confirmed complete response (CR) or partial response (PR) until the date of disease progression or death from any cause, whichever came first, assessed up to 24 months.
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie delle vie biliari
- Neoplasie delle vie biliari
- Agenti antineoplastici, immunologici
- Agenti antineoplastici
- Meccanismi molecolari dell'azione farmacologica
- Terapie
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Inibitori del checkpoint immunitario
- Terapia farmacologica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- K9903
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .